14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
QNRX vs SRZN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Quoin Pharmaceuticals, Ltd. (QNRX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). QNRX carries a Unified Composite Score of 46.1/100 (HOLD) at $3.28 (N/M Forward P/E, 0.0% operating margin), whereas SRZN carries 36.0/100 (SELL) at $28.46 (N/M Forward P/E, -485.4% operating margin).
Composite vs. Pillar Nuance: While QNRX currently prints a higher short-term Unified Composite Score (46.1/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. 0.0% operating margin) and revenue trajectory (+408.6% vs. +0.0% YoY).
Technical & Structure Timing Caution: QNRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5); meanwhile SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QNRX vs SRZN. Trailing 12-month operating profitability (QNRX 0.0% vs SRZN -485.4%) and valuation multiples (QNRX N/M vs SRZN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $642.7M market capitalization and -485.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ QNRX vs SRZN Key Questions & Quantitative Answers
As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Quoin Pharmaceuticals, Ltd. (QNRX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). QNRX carries a Unified Composite Score of 46.1/100 (HOLD) at $3.28 (N/M Forward P/E, 0.0% operating margin), whereas SRZN carries 36.0/100 (SELL) at $28.46 (N/M Forward P/E, -485.4% operating margin). Composite vs. Pillar Nuance: While QNRX currently prints a higher short-term Unified Composite Score (46.1/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. 0.0% operating margin) and revenue trajectory (+408.6% vs. +0.0% YoY). Technical & Structure Timing Caution: QNRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5); meanwhile SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SRZN leads the Growth & Scale pillar: QNRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SRZN at +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin). On trailing 12-month operating scale, QNRX generates N/A in USD-normalized revenue versus $11M for SRZN. In operating R&D and SG&A reinvestment, QNRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRZN.
QNRX and SRZN trade at balanced relative valuation multiples. QNRX trades at N/M Forward P/E, 7.6x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 52.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against QNRX (-142.6% ROE) versus SRZN (-62.8% ROE) capital efficiency.
In options market volatility and institutional positioning, QNRX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 74% Vol realized risk). By comparison, SRZN carries 72.0% implied volatility (13th %ile, Compressed (<25th %ile)), a 21.00x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.29β · 73% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.